ATAI
HealthcareAtaiBeckley Inc.
$3.87
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
AtaiBeckley Inc. operates within the healthcare sector and biotechnology industry. The company has a significant market presence with a market capitalization of $1.41 billion, annual revenue of $3.02 million, and approximately 54 employees. Financially, AtaiBeckley Inc. exhibits substantial losses, with net income totaling -$154,192,000 over the trailing twelve months. EBITDA stands at -$101,424,000, while free cash flow is -$39,028,624. The company maintains a considerable cash reserve of $114.61 million but carries a debt of $5.46 million. Key metrics such as gross margin (83.9%), operating margin (-3796.5%), and profit margin (0.0%) indicate significant operational challenges. AtaiBeckley Inc.'s valuation stands out with a forward P/E ratio of -7.93, suggesting potential concerns regarding future earnings performance. The price to sales ratio is substantial at 465.75, which may be attributed in part to the company's rapid revenue growth rate (1772.5% year-over-year). However, this metric should be considered within the context of overall financial and operational performance.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is headquartered in Amstelveen, The Netherlands.
Visit website →Key Statistics
- Market Cap
- $1.41B
- P/E Ratio
- N/A
- 52-Week High
- $6.75
- 52-Week Low
- $1.15
- Avg Volume
- 5.05M
- Beta
- 1.62
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Netherlands
- Employees
- 54